Lupin gets USFDA nod for generic cough relief oral solution

Hydrocodone Bitartrate and Homatropine Methylbromide is indicated for the symptomatic relief of cough in adults and children 6 years of age and older.

NEW DELHI: Drug firm Lupin has received approval from the US health regulator for generic Hydrocodone Bitartrate and Homatropine Methylbromide oral solution used for providing relief of cough.

The company has received US Food and Drug Administration (USFDA) approval for its generic Hydrocodone Bitartrate and Homatropine Methylbromide oral solution (Syrup) 5 mg/1.5 mg per 5 ml, Lupin said in a BSE filing.

The product is generic version of Endo Pharmaceuticals Inc's Hycodan oral solution in the same strength, it added.

Hydrocodone Bitartrate and Homatropine Methylbromide is indicated for the symptomatic relief of cough in adults and children 6 years of age and older.

Shares of Lupin Ltd today closed at Rs 1,440.15 per scrip on BSE, up 0.57 per cent from its previous close.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

Related Companies

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Lupin gets USFDA nod for generic cough relief oral solution
Text Size:AAA
Success
This article has been saved

*

+